Objective: Periodontal diseases are multifactorial infections that lead to destruction of the periodontal structures, including the tooth supporting tissues, periodontal ligament, and alveolar bone. The present study was designed to verify effect of Ankaferd Blood Stopper® (ABS) in conjunction with β tricalcium phosphate (β-TCP) on healing of periodontal intrabony defects. Subjects and Methods: A total of 20 intrabony periodontal defects were treated in ten patients with periodontal pocket depth (PPD) ≥ 6 mm and radiographic osseous defect depth ≥ 4 mm. The split mouth design was performed; In the 1st group (control group) ten defects were treated by β-TCP, while in the 2nd group (test group) ten defects were treated by mixing 0.5 ml of ABS with β-TCP. Phase I therapy was completed for all chosen patients to provide an oral environment more favorable for wound healing. Plaque index (PI), Gingival index (GI), Periodontal pocket depth (PPD) and clinical attachment level (CAL) were assessed for all patients. All indices were recorded at baseline, 6 and 12 months after surgery by the same operator. Radiographic measurements of bone density, M-D width of the defect and depth of the defect (DB) were also performed at the same time periods of recording the clinical parameters. Results: β-TCP/ABS group showed less mean plaque index, gingival index, clinical attachment loss, M-D width of the defect , depth of the defect and higher mean bone density than β-TCP group. Conclusion: Both treatment modalities demonstrated minimal inflammatory signs around teeth. Ankaferd Blood Stopper® combined with Beta tricalcium phosphate may enhance the healing and regenerative processes and lead to more bone fill, as well as density, compared to β tricalcium phosphate alone.